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1057-221 Safety of Combination Therapy With Once-Daily Niacin 
Extended-Release/Lovastatin in Over 4,000 Patients 
Participating in the Impact of Medical Subspecialty on 
Patient Compliance to Treatment Study 
Mark E. McGovern, Eugenlo A. Cefali, Suzanne Balandis, Rosemary Evans, Deborah L. 
Kennedy, Phillip D. Simmons, William M. Gentry, Kos Medical Research Institute, Miami, 
FL 
Background: Statins have a small risk of liver and muscle toxicity. Isolated case reports 
suggest that the combination of certain niacin preparations and statins may increase the 
risk. We evaluated the safety of a once-daily niacin extended-releasellovastatin (ERNL) 
drug combination when dosed as initial therapy in over 4,000 patients enrolled in the 
Impact of Medical subspecialty on PAtient Compliance to Treatment (IMPACT) study. 
Methods: IMPACT was a multicenter, open-label study in dyslipidemic men or women at 
over 1,000 sites across the United States. The study had two aims. One was to evaluate 
effects of ERNL on liver test elevations, creatine kinase (CK) levels, and drug-induced 
myopathy. A second aim was to evaluate patient compliance patterns among medical 
subspecialties and across geographic regions. Eligible patients began treatment with one 
500120 (mg niacin extended releaselmg lovastatin) tablet once-daily at bedtime. After the 
first month, the dose was increased to two 500/20 tablets (total dose of 1000/40), which 
was continued through week 12. 
Results: Preliminary results for CK, alanine aminotransferase (ALT), and aspartate ami- 
notransferase (AST) are shown below. The incidence of treatment-emergent elevated 
AST or ALT greater than 3 times upper limit was < 0.5%. No confirmed cases of drug- 
induced myopathy or rhabdomyolysis were observed. 
Conclusions: We conclude that Initial therapy with ERNL was safe and associated with 
a very low incidence of elevated liver tests. 
Preliminary IMPACT Results From i4,lOO Patients 
Baseline Week 8 
EANL Dose 0 1000/40 
CK mean (SE) 126 (1.8) 150 (2.8) 
CK median 102 115 
ALT mean (SE) 27 (0.2) 26 (0.2) 
ALT median 24 23 
AST mean (SE) 23 (0.1) 24 (0.1) 
AST m&an 22 23 
SE = standard error 
Week 12 
1000/40 
148 (2.1) 
116 
26 (0.3) 
23 
25 (0.3) 
23 
1057-222 Safety, Efficacy, and Effect on Glucose Levels of Once- 
Daily Niacin on Patients With Dyslipidemia 
Rosario A. Mercado-Younq, Liberty 0. Yaneza, Swangjit Suraamornkul, Judith J. 
Nicastro. Shuko Lee, Robert J. Chilton. Robelt A. O’Rourke, University of Texas Health 
Science Center, San Antonio, TX 
Background: Nicotinic acid exerts Its lipld-lowering effect by inhibiting the production of 
VLDL particles by the liver, and consequently reducing the LDL level and raising HDL 
cholesterol. A once-daily extended release (ER) niacin formulation has lesser side 
effects as compared to immediate release niacin. However, glucose intolerance may 
occur causing concerns in using the drug in diabetics. 
Methods: A consecutive sample of 90 patients taking Extended-Release (ER) Niaspan 
from June 1999 to June 2002 was collected. Primary outcomes were glucose and lipo- 
protein cholesterol response, alterations in hepatic enzymes and other side effects as 
documented from the patient’s medical records. 
Results: A total sample of ninety patients, age 60.1 f 0.98 treated for 1 to 12 months 
with ER Niaspan was collected. Fifty six (62%) were diabetics. Baseline characteristics 
between diabetics and nondlabetics were homogeneous except for angiotensin-enzyme 
inhibitor (ACE-l) which is given to most diabetics. Extended Release (ER) Niaspan was 
initiated at a dose of 500 mo/dav to a maximum of 2.000 ma/d. ER Niaspan resulted in 
significant reduction from baselme at all treatment levels of LDL cholesterol The mean 
oercent chanoe LDL at mean baseline value of 97 mold1 was 6.8% at 500 ma. 9.4% at 
1,000 mg, 14% at 1,500 mg. and 14.2% at 2,000 mg. The mean percent change HDL 
mcreased from mean baseline value of 35 mgidl and was significantly increase only at 
>l,OOO mg dose. The mean percent change in HbA, C from a mean baseline value of 
6.65 (0.28) in diabetics did not change significantly in all treatment groups, 0.003 at 500 
mg, 0.1 at 1,000 mg. 0.2 at 1,500 mg and 0.01 and 2000 mg. There was a small mean 
percent change in fasting plasma glucose (FPG) from baseline value of 149 mgldl 
(29.42) at 1000 mg dose but did not become worse when given continuously. There was 
no significant increase from baselme mean values in SGOT and SGPT. The adverse 
events noted were flushing (0.2%), skin rash (.2%), and pruritus (0.2%). 
Conclusion: Thus, extended release niacin alters favorably the lipoprotein profile and is 
generally well tolerated even in the diabetic population. 
1057-223 Converting Patients Intolerant of Simvastatin to 
Atorvastatin Is a Safe Practice and Associated With 
Significant Improvement in Lipid Control and Less 
Creatine Kinase Elevation 
Richard A. Krasuski, Dennis L. Doeppenschmldt, Rachel L. Beck, J. Steven Henry, 
Christopher M. Thompson, Wilford Hall Medical Center, San Antonio, TX 
Background: Several health mantenance and preferred provider organizations have 
limlted their formularies for economic reasons. At our institution atolvastatin can only be 
used for patients who have first failed simvastatin therapy. The goal of our study was to 
assess whether converting patients intolerant to simvastatin over to atorvastatin was safe 
and feasible. 
Methods: We examined all patients converted from simvastatin to atorvastatin between 
October 2000 and March 2002 at our medical center’s lipid clinic, which currently follows 
2500 patients. Clinical characteristics and fasting chemistry data were prospectively 
entered into a database during clinic visits. 
Results: One-hundred and four patients had their lipid therapy swtched during the 
oeriod of observation. The mean aoe was 68 +/- 9 years and 24% were women. The pri- 
mary reason for changing therapy was inadequate low-density lipoprotein (LDL) choles- 
terol control in 57%. inadeauate trialvceride control in 9%. and creatine kinase (CK) 
elevation in 24% (3 patients had rhabdomyolysis). All patients tolerated atorvastatin dur- 
ing the median follow-up period of 6 months. The median simvastatin dose was 80 mg 
with 33% of patients on concurrent gemfibrozil. Median atowastatin dose was 80 mg with 
13% on concurrent gemfibrozil. Lipid panels dramatically improved, with reduction in total 
cholesterol from 211 +I- 44 mgldl on simvastatin to 165 +/- 26 mgldl on atorvastatin 
(pcO.001). LDL cholesterol was reduced from 128 +/- 32 to 91 +/- 20 mg/dl (pcO.001) and 
triglycerides from 160 (range 58.681) to 133 mg/dl (range 32-415) (p<O.OOl), while high- 
density lipoprotein cholesterol was unchanged (46 +/- 11 vs. 45 +I-1 1 mgldl. p=O.406). 
CK levels dropped from a median of 120 to 100 (p<O.OOl) and AST was unchanged after 
conversion to atorvastatin. 
Conclusion: Atorvastatin is extremely well tolerated in patients switched from simvasta- 
tin. LDL cholesterol and triglycerides improve dramatlcally, with no appreciable change in 
HDL levels. Creatine kinase levels are significantly less elevated with atorvastatin and no 
rhabdomyolysis was seen over a median follow-up period of 6 months, even I” patients 
havmg had rhabdomyolysis with simvastatin. 
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1058-l 23 Late Aortic Systolic Pressure Augmentation and 
Increased Pulse Pressure in Treated Hypertensive 
Patients 
Marcus C. Sims, Rahul Aggamal, Juan Estrada. Wilmer W. Nichols, University of 
Florida, Gainesville, FL 
Backgrounct Elevated aortic pulse pressure resulting from increased arterial stiffness is 
a powerful independent predictor of adverse cardiovascular events. The measured aortic 
pressure wave is composed of a forward traveling wave and a reflected wave. Aotiic 
augmentation index (A&) is a measure of arterial stiffness and can be obtained as the 
ratio of reflected wave amplitude and pulse pressure. The objective of anti-hypertensive 
drug therapy should be to decrease Ag by lowering reflected wave amplitude and reduc- 
ing pulse pressure and left ventricular (LV) oxygen demand. Accordingly, the aim of this 
study was to investigate the effectiveness of anti-hypertensive drug therapy on central 
aoriic wave reflection characteristics in treated hypertensw patients. 
Methods Radial artery pressure waves were recorded by applanatlon tonometry and 
ascending aortic pressure waves generated using a generalized transfer function in 19 
hypertensive patients taking one or more anti-hypertensive drugs and 19 healthy normo- 
tensive subjects matched for height, weight and heart rate. Ag. reflected wave amplitude 
and myocardial oxygen supply/demand ratio were calculated from the generated aoriic 
pressure wave. 
Results Sphygmomanometer measured brachial diastolic (71*11 vs 75i7.2 mm Hg, 
p=NS) and mean (95*15 vs 89e7.5 mm Hg, p=NS) pressures were similar in the two 
groups and were withtn normal limits while Al, (26&O vs 3.2e6.7 %. pcO.001) and 
reflected wave amplitude (15+8.0 vs 1 .Otl.6 mm Hg, p<O.OOl) were abnormally high in 
the treated hypertenwe group resulting I” elevated late aortic systolic (127+21 vs 
105+8.7 mm Hg, pcO.01) and pulse (55*15 vs 28i6.2 mm Hg, pcO.001) pressures and 
decreased myocardial oxygen supply/demand ratio (I .5+0.3 vs 1.7+0.3, ~~0.05). 
Conclusion. In hypertensive patients with increased aortic stiffness early return of 
reflected pressure waves to the proximal aorta augments systolic pressure in late systole 
and increases pulse pressure. These changes cause the ventricle to expend wasted 
energy resulting I” an imbalance between myocardial oxygen supply and demand 
despite adequate treatment as assessed by standard sphygmomanometer measure- 
ments. 
